Drug Profile
Idarubicin liposomal
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator BC Cancer Agency; Celator Pharmaceuticals
- Class Antineoplastics; Cytostatic antibiotics; Daunorubicins
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 19 Apr 2006 No development reported - Preclinical for Acute myeloid leukaemia in Canada (unspecified route)
- 16 Dec 2003 Preclinical trials in Acute myeloid leukaemia in Canada (unspecified route)